All > Metastatic Lung Cancer > Lung Cancer

carboplatin for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Jonsson Comprehensive Cancer Center, Los Angeles, CANon-Small Cell Lung Cancer+8 Morecarboplatin - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new way to give radiation and chemotherapy to patients with stage II-III NSCLC that can't be removed by surgery. The new way may kill more tumor cells and spare more healthy tissue.

Eligible Conditions
  • Non-Small Cell Lung Cancer
  • Squamous Cell Carcinoma of the Lung
  • Stage IIIA Non-small Cell Lung Cancer
  • Stage IIB Non-small Cell Lung Cancer
  • Lung Adenocarcinoma
  • Stage IIA Non-small Cell Lung Cancer
  • Non-small Cell Lung Cancer (NSCLC), Recurrent
  • Adenosquamous Cell Lung Cancer
  • Non-small Cell Lung Cancer Stage IIIB

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
CBD 400mg
1
Summer STRIPES
1
Vestibular Intervention via Portable Electrical Stimulator (VIPES) system

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: participants will be followed for 2 years

Year 2
Overall survival
To determine Lung cancer Disease specific survival
Year 2
To determine tumor Local control
up to 90 days
Non-Small Cell Lung Carcinoma

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
CBD 400mg
1
Summer STRIPES
1
Vestibular Intervention via Portable Electrical Stimulator (VIPES) system

Side Effects for

Chemotherapy
58%Neutropenia
45%Nausea
36%Fatigue
34%Alopecia
30%Constipation
30%Vomiting
28%Anaemia
24%Thrombocytopenia
19%Abdominal pain
19%Diarrhoea
18%Drug hypersensitivity
16%Leukopenia
14%Asthenia
12%Pruritus
11%Headache
9%Bone pain
9%Rash
8%Oedema peripheral
8%Dizziness
8%Dyspepsia
8%Myalgia
7%Phlebitis
7%Dysgeusia
7%Dyspnoea
7%Insomnia
7%Pain in extremity
5%Peripheral sensory neuropathy
5%Arthralgia
5%Abdominal distension
5%Decreased appetite
5%Cough
5%Neuropathy peripheral
5%Paraesthesia
4%Back pain
4%Febrile neutropenia
4%Stomatitis
4%Pyrexia
4%Epistaxis
3%Musculoskeletal pain
3%Flushing
3%Abdominal pain upper
3%Lethargy
3%Nasopharyngitis
3%Urinary tract infection
3%Erythema
1%Large intesting perforation
1%Appendicitis
1%Dry skin
1%Obstruction
1%Chest pain
1%Hemorrhoids
1%Pulmonary embolism
1%Dehydration
1%Ascites
1%Sinusitis
1%Muscle spasms
1%Mucosal inflammation
This histogram enumerates side effects from a completed 2008 Phase 2 trial (NCT02004093) in the Chemotherapy ARM group. Side effects include: Neutropenia with 58%, Nausea with 45%, Fatigue with 36%, Alopecia with 34%, Constipation with 30%.

Trial Design

1 Treatment Group

Treatment (dose-escalation of RT)
1 of 1

Experimental Treatment

29 Total Participants · 1 Treatment Group

Primary Treatment: carboplatin · No Placebo Group · N/A

Treatment (dose-escalation of RT)Experimental Group · 6 Interventions: stereotactic body radiation therapy, carboplatin, paclitaxel, hypofractionated radiation therapy, laboratory biomarker analysis, image-guided radiation therapy · Intervention Types: Radiation, Drug, Drug, Radiation, Other, Radiation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
stereotactic body radiation therapy
2019
Completed Phase 2
~470
Carboplatin
FDA approved
Paclitaxel
FDA approved
hypofractionated radiation therapy
2008
Completed Phase 3
~290
image-guided radiation therapy
2008
Completed Phase 2
~180

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: participants will be followed for 2 years

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor
341 Previous Clinical Trials
21,531 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,163 Previous Clinical Trials
41,167,236 Total Patients Enrolled
Percy LeePrincipal InvestigatorJonsson Comprehensive Cancer Center
1 Previous Clinical Trials
2 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Frequently Asked Questions

To what extent is the study participant pool expanding?

"This clinical trial has ceased recruitment, with the posting dated March 23rd 2011 and its last update on December 2nd 2021. For those still looking for medical studies, 1949 trials involving lung cancer are currently open to applicants as well as 1177 trails offering carboplatin treatment." - Anonymous Online Contributor

Unverified Answer

What conditions does carboplatin typically address?

"Physcians can utilise carboplatin to aid in the management of melanoma, neoplasm metastasis, and non-hodgkin lymphoma." - Anonymous Online Contributor

Unverified Answer

Is enrollment for this trial still open to the public?

"This clinical trial is not actively recruiting participants. The initial post date was March 23, 2011 and the last update occurred on December 2nd of 2021. However there are 1949 studies related to lung cancer and 1177 trials involving carboplatin that are currently searching for eligible candidates." - Anonymous Online Contributor

Unverified Answer

What additional experiments have occurred involving carboplatin?

"Presently, 1177 clinical trials are in progress studying the effects of carboplatin with 333 of them being Phase 3. Concentrated mainly around Shanghai, there are 66707 medical centres examining this medication." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top